Abstract:Three clinicopathological phases of chronic hepatitis B virus (HBV) infection are identified. First, is immune tolerance of HBV. High levels of viraemia are associated with normal alanine aminotransferase (ALT) levels and minimal histological lesions. More than 30-40% of hepatocytes have the hepatitis B core antigen (HBcAg), predominantly in their nuclei. Maternally derived hepatitis B e antigen (HBeAg) crossing the placenta may result in the elimination of T helper cells responsive to HBeAg/HBcAg. This phase can last for periods ranging from a few weeks to 10 or more years until the immune tolerance is lost. Second, is the immune clearance of HBV. Intermediate levels of viraemia are associated with fluctuating ALT levels and active and ongoing hepatitis. Approximately 20-30% of hepatocytes have HBcAg, predominantly in their cytoplasm. Expression of pre-core defective HBV mutants during chronic HBV infection may lead to a reduction in the secretion of HBeAg and may trigger the beginning of the immuno-elimination phase. The mechanism of intrahepatic shift of HBcAg from the nucleus to the cytoplasm and the decreased levels of viraemia in this phase may be, at least in part, secondary to liver damage and regeneration. Third, is latent infection with residual integrated HBV. Undetectable viraemia is associated with normal ALT levels and no virus-induced liver damage. With regard to hepatocyte expression of HBsAg in chronic HBV infection, membrane staining of HBsAg on hepatocytes has been shown to correlate well with the presence of viraemia. The degree of cytoplasmic hepatitis B surface antigen (HBsAg) expression inversely correlates with the level of viraemia. Therefore, HBsAg carriers with high levels of viraemia have low levels of cytoplasmic hepatitis B surface antigen (HBsAg) expression, while those with low levels of viraemia have high levels of cytoplasmic HBsAg expression. However, several exceptions have been identified. High levels of viraemia associated with high levels of cytoplasmic HBsAg expression were recognized in patients with fibrosing cholestatic hepatitis. In contrast, low levels of viraemia associated with low levels of cytoplasmic HBsAg expression were recognized in patients with hepatitis C virus but not hepatitis D virus superinfection.

Binding of biotin to hepatitis B surface antigen: a possible pitfall in immunohistochemistry.

[Relation Between Beta-2-glycoprotein I and Hepatitis B Virus Surface Antigen].

The Clinical Significance of Up-Converting Phosphor Immunochromatography in Detecting Hepatitis B Virus Large Envelope Protein in Various Types of Chronic Liver Disease

Factors affecting binding of beta 2-glycoprotein Ⅰ to hepatitis B surface antigen in the serum of patients with chronic hepatitis B

Studies on Specific Interaction of Beta-2-Glycoprotein I with Hbsag

Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile

Binding with a Large Quantity of Hapten Dinitroflorobenzene Lowers the Antigenicity of Hepatitis B Surface Antigen

Detection of hepatitis B virus DNA in serum and relation with the IgM class anti-HBc titers in hepatitis B virus infection

Serum Biomarkers Of Hepatitis B Virus Infected Liver And Methods For Detection Thereof

Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of the lymphocytes.

Model for studying virus attachment. II. Binding of biotinylated human T cell leukemia virus type I to human blood mononuclear cells potential targets for human T cell leukemia virus type I infection

A trichrome stain for the intrahepatic localization of the hepatitis B surface antigen (HBsAg)

Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia

Biotin as a masking agent in chorionic gonadotropin assays utilizing biotinylated antibodies

Significance of anti-HBc alone serological status in clinical practice

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry.

[Studies on the Association Between Beta 2-Glycoprotein I and Hepatotropism of Hepatitis B Virus].

A possible receptor for β2 glycoprotein I on the membrane of hepatoma cell line smmc7721

Natural history of chronic hepatitis B virus infection: An immunopathological study

Analysis of Complement‐Bound Hepatitis B Virus Complexes by an Immuno‐Capture Polymerase Chain Reaction Method

Identification and Characterization of Peptides That Interact with Hepatitis B Virus Via the Putative Receptor Binding Site.